All In Biotech

Drug Trial Radar · NCT07570186

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

A Randomized, Open-label, Single-dose, Crossover Phase 1 Clinical Trial to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety/Tolerability of JPI-547 After a Single Oral Administration in Healthy Male Korean, Caucasian and Chinese Participants

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.

Conditions

  • Healthy Volunteers

Interventions

  • JPI-547Drug

    JPI-547 is administered orally as a single dose per administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of JPI-547Time frame: Pre-dose through 120 hours post-dose after each administration, based on 17 PK samples per administration; assessed up to Day 20 for the Korean/Caucasian fed/fasted crossover arm and up to Day 6 for the Chinese fasted arm.
  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of JPI-547Time frame: Pre-dose through 120 hours post-dose after each administration, based on 17 PK samples per administration; assessed up to Day 20 for the Korean/Caucasian fed/fasted crossover arm and up to Day 6 for the Chinese fasted arm.
  3. Number of Participants With Abnormalities in Safety and Tolerability AssessmentsTime frame: From the first administration of JPI-547 until the Post-Study Visit; assessed up to Day 32 for the Korean/Caucasian fed/fasted crossover arm and up to Day 18 for the Chinese fasted arm.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.